| Symbol | MCRB |
|---|---|
| Name | SERES THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 200 SIDNEY STREET,4TH FLOOR, CAMBRIDGE, Massachusetts, 02139, United States |
| Telephone | +1 617 945-9626 |
| Fax | — |
| — | |
| Website | https://www.serestherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001609809 |
| Description | Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the companys product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401. Additional info from NASDAQ: |
📋 TERESA L YOUNG (Officer) plans to sell 167 shares of SERES THERAPEUTICS, INC. (at $7.69 each, total $1K) Filed: May 19, 2026 | ID: 004748
Read moreShaff Eric D. 🟡 adjusted position in 259 shares (2 derivative) of Seres Therapeutics, Inc. (MCRB) at $7.53 Transaction Date: May 15, 2026 | Filing ID: 230733
Read moreDesRosier Thomas 🟡 adjusted position in 79 shares (2 derivative) of Seres Therapeutics, Inc. (MCRB) at $7.53 Transaction Date: May 15, 2026 | Filing ID: 230728
Read moreHenn Matthew R 🟡 adjusted position in 77 shares (2 derivative) of Seres Therapeutics, Inc. (MCRB) at $7.53 Transaction Date: May 15, 2026 | Filing ID: 230727
Read moreBrady Kelly 🟡 adjusted position in 59 shares (2 derivative) of Seres Therapeutics, Inc. (MCRB) at $7.53 Transaction Date: May 15, 2026 | Filing ID: 230732
Read moreSeres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
Read more(30% Negative) SERES THERAPEUTICS, INC. (MCRB) Reports Q2 2026 Financial Results
Read moreSeres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Read moreNew Form DEFA14A - Seres Therapeutics, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001140361-26-017092 <b>Size:</b> 1 MB
Read moreSeres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT02437500 | Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Cl… | — | Clostridioides Difficile Infection | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT04995653 | A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER… | Phase1 | Allogeneic Hematopoietic Stem Cell Transplantation | Completed | 2021-11-24 | 2024-07-23 | ClinicalTrials.gov |
| NCT03817125 | Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention | Phase1 | Metastatic Melanoma | Completed | 2019-01-28 | 2022-03-04 | ClinicalTrials.gov |
| NCT03759041 | A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-… | Phase2 | Ulcerative Colitis | Terminated | 2018-12-19 | 2021-10-13 | ClinicalTrials.gov |
| NCT03183141 | ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides … | Phase3 | Clostridioides Difficile Infection | Completed | 2017-10-23 | 2022-04-29 | ClinicalTrials.gov |
| NCT03183128 | ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent … | Phase3 | Clostridium Difficile Infection | Completed | 2017-07-10 | 2020-09-29 | ClinicalTrials.gov |
| NCT02830542 | SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection t… | Phase1 | Clostridium Difficile Infection | Completed | 2016-08-01 | 2018-08-01 | ClinicalTrials.gov |
| NCT02618187 | A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287… | Phase1 | Ulcerative Colitis | Completed | 2016-01-13 | 2018-01-26 | ClinicalTrials.gov |
| NCT02437487 | SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RC… | Phase2 | Clostridium Difficile | Completed | 2015-05-01 | 2016-10-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Clostridium Difficile | COMPLETED | NCT02437487 |
| SER-109 | Other | Phase PHASE2 | Clostridium Difficile | COMPLETED | NCT02437487 |
| Vancomycin Pre-Treat | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT02618187 |
| Placebo Pre-Treat | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT02618187 |
| Placebo | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT02618187 |
| SER-287 | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT02618187 |
| Placebo for SER-287 | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT03759041 |
| SER-287 | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT03759041 |
| Placebo for Vancomycin Pre-Treatment | Drug | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT03759041 |
| Vancomycin Pre-Treatment | Drug | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT03759041 |
| Placebo | Other | Phase PHASE1 | Clostridium Difficile Infection | COMPLETED | NCT02830542 |
| SER-262 | Other | Phase PHASE1 | Clostridium Difficile Infection | COMPLETED | NCT02830542 |
| SER-109 | Other | Phase PHASE3 | Clostridioides Difficile Infection | COMPLETED | NCT03183141 |
| Placebo | Other | Phase PHASE3 | Clostridium Difficile Infection | COMPLETED | NCT03183128 |
| SER-109 | Other | Phase PHASE3 | Clostridium Difficile Infection | COMPLETED | NCT03183128 |
| SER-109 | Other | Preclinical | Clostridioides Difficile Infection | APPROVED_FOR_MARKETING | NCT02437500 |
| SER-401 | Other | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT03817125 |
| Matching Placebo for SER-401 | Other | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT03817125 |
| Nivolumab | Other | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT03817125 |
| Vancomycin pretreatment | Drug | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT03817125 |
| Placebo for antibiotic | Other | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT03817125 |
| SER-155 Placebo | Other | Phase PHASE1 | Allogeneic Hematopoietic Stem Cell Transplantation | COMPLETED | NCT04995653 |
| SER-155 | Other | Phase PHASE1 | Allogeneic Hematopoietic Stem Cell Transplantation | COMPLETED | NCT04995653 |
| Vancomycin Placebo | Other | Phase PHASE1 | Allogeneic Hematopoietic Stem Cell Transplantation | COMPLETED | NCT04995653 |
| Vancomycin Pre-Treatment | Drug | Phase PHASE1 | Allogeneic Hematopoietic Stem Cell Transplantation | COMPLETED | NCT04995653 |
| SER-155 Placebo | DRUG | Phase PHASE1 | Allogeneic Hematopoietic Stem Cell Transplantation | COMPLETED | NCT04995653 |
| SER-155 | DRUG | Phase PHASE1 | Allogeneic Hematopoietic Stem Cell Transplantation | COMPLETED | NCT04995653 |
| Vancomycin Placebo | DRUG | Phase PHASE1 | Allogeneic Hematopoietic Stem Cell Transplantation | COMPLETED | NCT04995653 |
| SER-401 | DRUG | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT03817125 |
| Matching Placebo for SER-401 | DRUG | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT03817125 |
| Nivolumab | DRUG | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT03817125 |
| Vancomycin pretreatment | DRUG | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT03817125 |
| Placebo for antibiotic | DRUG | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT03817125 |
| Placebo for SER-287 | DRUG | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT03759041 |
| Placebo for Vancomycin Pre-Treatment | DRUG | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT03759041 |
| Vancomycin Pre-Treatment | DRUG | Phase PHASE1 | Allogeneic Hematopoietic Stem Cell Transplantation | COMPLETED | NCT04995653 |
| SER-262 | DRUG | Phase PHASE1 | Clostridium Difficile Infection | COMPLETED | NCT02830542 |
| Vancomycin Pre-Treat | DRUG | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT02618187 |
| Placebo Pre-Treat | DRUG | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT02618187 |
| SER-287 | DRUG | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT03759041 |
| Placebo | DRUG | Phase PHASE3 | Clostridium Difficile Infection | COMPLETED | NCT03183128 |
| SER-109 | BIOLOGICAL | Phase PHASE3 | Clostridioides Difficile Infection | COMPLETED | NCT03183141 |